In this final analysis of a phase @ , randomised , multicentre , double-blind study , patients aged @ months to @ years with a documented malignancy who were scheduled to receive either moderately or highly emetogenic chemotherapy were randomly assigned with an interactive voice response system to an age-based and weight-based blinded regimen of aprepitant ( @ mg for ages @-@ years ; @ mg/kg up to @ mg for ages @ months to < @ years ) plus ondansetron on day @ , followed by aprepitant ( @ mg for ages @-@ years ; @ mg/kg up to @ mg for ages @ months to < @ years ) on days @ and @ , or placebo plus ondansetron on day @ followed by placebo on days @ and @ ; addition of dexamethasone was allowed .